诊断学理论与实践

诊断学理论与实践 >

2021 , Vol. 20 >Issue 05: 507 - 511

DOI: https://doi.org/10.16150/j.1671-2870.2021.05.016

综述

多发性骨髓瘤相关生物标志物的研究进展

展开
  • 1.浙江省绍兴市中心医院血液科,浙江 绍兴 312030
    2.上海交通大学医学院附属瑞金医院血液科,上海 200025

收稿日期: 2020-10-01

  网络出版日期: 2022-06-28

收起

本文引用格式

赵建治, 糜坚青 . 多发性骨髓瘤相关生物标志物的研究进展[J]. 诊断学理论与实践, 2021 , 20(05) : 507 -511 . DOI: 10.16150/j.1671-2870.2021.05.016

参考文献

[1] Wang S, Xu L, Feng J, et al. Prevalence and Incidence of Multiple Myeloma in Urban Area in China: A National Population-Based Analysis[J]. Front Oncol, 2020,9:1513.
[2] Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients[J]. Leukemia, 2014,28(5):1122-1128.
[3] Cohen AD. CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update[J]. Am Soc Clin Oncol Educ Book, 2018,38:e6-e15.
[4] Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group[J]. J Clin Oncol, 2015,33(26):2863-2869.
[5] Ong SY, de Mel S, Chen YX, et al. Early relapse post autologous transplant is a stronger predictor of survival compared with pretreatment patient factors in the novel agent era: analysis of the Singapore Multiple Myeloma Working Group[J]. Bone Marrow Transplant, 2016,51(7):933-937.
[6] Moreau P, Attal M, Caillot D, et al. Prospective evaluation of magnetic resonance imaging and [18F]Fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM study[J]. J Clin Oncol,2017, 35(25):2911-2918.
[7] Rasche L, Angtuaco E, McDonald JE, et al. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma[J]. Blood, 2017,130(1):30-34.
[8] Özkurt ZN, Sucak GT, Akı ŞZ, et al. Early prognostic value of monitoring serum free light chain in patients with multiple myeloma undergoing autologous stem cell transplantation[J]. Cancer Invest, 2017,35(3):195-201.
[9] 李璐, 姜华, 傅卫军, 等. 血清游离轻链比值及差值对初诊多发性骨髓瘤患者预后价值的评估与比较[J]. 中华血液学杂志, 2019,40(4):321-326.
[10] Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report[J]. Cancer Res, 2004,64(4):1546-1558.
[11] Munshi NC, Anderson KC, Bergsagel PL, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2[J]. Blood, 2011,117(18):4696-700.
[12] Avet-Loiseau H, Leleu X, Roussel M, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)[J]. J Clin Oncol, 2010,28(30):4630-4634.
[13] Walker BA, Wardell CP, Brioli A, et al. Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients[J]. Blood Cancer J, 2014,4(3):e191.
[14] Shaughnessy JD Jr, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1[J]. Blood, 2007,109(6):2276-2284.
[15] Dickens NJ, Walker BA, Leone PE, et al. Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome[J]. Clin Cancer Res. 2010 Mar 15; 16(6):1856-64.
[16] Lahuerta JJ, Paiva B, Vidriales MB, et al. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials[J]. J Clin Oncol, 2017,35(25):2900-2910.
[17] Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma[J]. Lancet Oncol, 2016,17(8):e328-e346.
[18] National Comprehensive Cancer Network.Multiple Myeloma (verson 2.2020).
[19] Paiva B, Vidriales MB, Cerveró J, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation[J]. Blood, 2008,112(10):4017-4023.
[20] Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma[J]. Blood, 2015,125(20):3059-3068.
[21] Puig N, Sarasquete ME, Balanzategui A, et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry[J]. Leukemia, 2014,28(2):391-397.
[22] Martinez-Lopez J, Lahuerta JJ, Pepin F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma[J]. Blood, 2014, 123(20):3073-3079.
[23] Walker BA, Boyle EM, Wardell CP, et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma[J]. J Clin Oncol, 2015,33(33):3911-3920.
[24] Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies[J]. Sci Transl Med, 2014,6(224):224ra24.
[25] Bianchi G, Kyle RA, Larson DR, et al. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma[J]. Leukemia, 2013,27(3):680-685.
[26] Gonsalves WI, Rajkumar SV, Gupta V, et al. Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma[J]. Leukemia, 2014,28(10):2060-2065.
[27] Paiva B, Puig N, Cedena MT, et al. Differentiation stage of myeloma plasma cells: biological and clinical significance[J]. Leukemia, 2017,31(2):382-392.
[28] Peceliunas V, Janiulioniene A, Matuzeviciene R, et al. Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma[J]. Leuk Lymphoma, 2012, 53(4):641-647.
[29] Kis O, Kaedbey R, Chow S, et al. Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates[J]. Nat Commun, 2017,8:15086.
[30] Mithraprabhu S, Khong T, Ramachandran M, et al. Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma[J]. Leukemia, 2017,31(8):1695-1705.
Options
文章导航

/

〈 〉